% MB % MB % 1. Wellness and Anti-aging 128.58 40.58% 162.70 43.82% 34.12 26.54% 2. Aesthetic Innovation 96.00 30.30% 67.17 18.09% (28.83) (30.03%) 3. Companion Animal Health 80.78 25.50% 132.19 35.60

-634-0225 Fax 02-634-0135 www.interpharma.co.th Type of Revenue 1st Quarter 2020 1st Quarter 2019 Change MB % MB % MB % 1. Wellness & Anti-Aging 47.77 49.18 31.87 37.52 15.90 49.90% 2. Aesthetic

commercially launched in September 2019, an increase in financial cost pressured by incremental debt financing to support business expansion which THB 5,357.8m loan facility to the acquisition of Outriggers was

(%) 5.30 5.83 (0.53) The decrease in 1Q18 net profit. Debt-to-Equity Ratio (x) 0.10 0.09 0.01 Slightly increase from incremental in account payable. For more information, please contact: Boontharika Boonkhum

the amount of Baht 984.0 million, increased by 17.7% compared with 9M16, in line with incremental in sales volume. The Company’s selling expenses reported at Baht 261.1 million decreased by 7.0

revenues for the year were 18.6% and 25.0%, respectively. The incremental of administrative expenses derived mainly from two reasons as the following: 1. Cost incurred from fully operational of new hospital

an increased sales proportion of higher profit margin products.  Cost of rental and rendering of services increased by Baht 13.4 million or 18.9% from Q3/2018 due to the incremental expenses from new

increased in revenues from sales of medicated pet shampoo, pet foods products, livestock animal products, and revenues from sales of wellness & anti-aging products and aesthetic innovations products. 2. Cost

shares of WCI Holding PCL, held by EFORL. As coronavirus situation may impact to the business which is unable to be expected, the Board of Director meeting considers that the investment in wellness

growth was driven primarily by an increase in revenues from sales of pet skincare shampoo products, pet food products and livestock animal products, and revenues from sales of wellness & anti-ageing